Taken together, these results show that the optimized V2 inverted chimeric siRNA demonstrates marked improvements in targeting both MYC and KRAS, resulting in attenuated MAPK signaling and synergistic inhibition of cancer cell viability. The gene discussed is KRAS; the disease is cancer.